세라마이드 (경구)

Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension.

1. Nat Commun. 2026 Jan 10;17(1):1534. doi: 10.1038/s41467-025-68256-5. Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension. Nordbeck P(1)(2), Goker-Alpan O(3), Bernat JA(4), Germain DP(5)(6), Giraldo P(7), Jovanovic A(8), K

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.

2. J Thorac Oncol. 2025 Oct;20(10):1517-1530. doi: 10.1016/j.jtho.2025.07.117. Epub 2025 Sep 9. Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial. Cho BC(1), Li W(2), Spira AI(3), Sauder M(4)

Efficacy and Safety of Oral Administration of Wine Lees Extract (WLE)-Derived Ceramides and Glucosylceramides in Enhancing Skin Barrier Function: A Randomized, Double-Blind, Placebo-Controlled Study.

3. Nutrients. 2024 Jul 1;16(13):2100. doi: 10.3390/nu16132100. Efficacy and Safety of Oral Administration of Wine Lees Extract (WLE)-Derived Ceramides and Glucosylceramides in Enhancing Skin Barrier Function: A Randomized, Double-Blind, Placebo-Controlled Study. Sanjaya A(1), Ishida A(1), Li X(1

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral AL01211 in Healthy Chinese Volunteers.

4. Clin Drug Investig. 2024 Jun;44(6):387-398. doi: 10.1007/s40261-024-01362-2. Epub 2024 May 2. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral AL01211 in Healthy Chinese Volunteers. Dong L(#)(1)(2), Xiang J(#)(3), Babcock M(3), Cheng Y(1)(2), Wang Y(1)(2), Shen Y(3), Li L

Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non-brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease.

5. Clin Pharmacol Drug Dev. 2024 Jun;13(6):696-709. doi: 10.1002/cpdd.1375. Epub 2024 Feb 16. Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non-brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease. Babcock M(1), Zheng J(1), Gail Shurr J(1

Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial.

6. JAMA Netw Open. 2022 Jan 4;5(1):e2144279. doi: 10.1001/jamanetworkopen.2021.44279. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. Liu S(1), D'Amico D(2), Shankland E(1), Bhayana S(1), Garcia JM(3)(4), Aebischer

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.

7. J Parkinsons Dis. 2022;12(2):557-570. doi: 10.3233/JPD-212714. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. Peterschmitt MJ(1

Chronic co-exposure to BPA and alcohol synergizes hepatotoxicity via dysregulation of glycerolipid metabolism and ceramide/HtrA2-driven apoptosis in HepG2 cells.

8. J Hazard Mater. 2026 Feb 15;504:141290. doi: 10.1016/j.jhazmat.2026.141290. Epub 2026 Jan 29. Chronic co-exposure to BPA and alcohol synergizes hepatotoxicity via dysregulation of glycerolipid metabolism and ceramide/HtrA2-driven apoptosis in HepG2 cells. Tan YQ(1), Shih CL(2), Chen YC(3), L

Synergistic effects of oral milk ceramide-collagen peptides mixtures in preventing UV-induced inflammation and photoaging through TGF-β and NF-κB/MAPK signaling pathways in UV-exposed hairless mice.

9. J Photochem Photobiol B. 2025 Jul;268:113171. doi: 10.1016/j.jphotobiol.2025.113171. Epub 2025 Apr 29. Synergistic effects of oral milk ceramide-collagen peptides mixtures in preventing UV-induced inflammation and photoaging through TGF-β and NF-κB/MAPK signaling pathways in UV-exposed hairle

Drug-drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics.

10. Br J Clin Pharmacol. 2025 Aug;91(8):2304-2315. doi: 10.1002/bcp.70037. Epub 2025 Mar 11. Drug-drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics. Li L(1), Zh

C6 ceramide motivates the anticancer sensibility induced by PKC412 in preclinical head and neck squamous cell carcinoma models.

11. J Cell Physiol. 2018 Dec;233(12):9437-9446. doi: 10.1002/jcp.26831. Epub 2018 Jul 3. C6 ceramide motivates the anticancer sensibility induced by PKC412 in preclinical head and neck squamous cell carcinoma models. Zhu Y(1), Wang C(1), Zhou Y(1), Ma N(1), Zhou J(1). Author information: (1)Dep

LPS and palmitate synergistically stimulate sphingosine kinase 1 and increase sphingosine 1 phosphate in RAW264.7 macrophages.

12. J Leukoc Biol. 2018 Oct;104(4):843-853. doi: 10.1002/JLB.3A0517-188RRR. Epub 2018 Jun 8. LPS and palmitate synergistically stimulate sphingosine kinase 1 and increase sphingosine 1 phosphate in RAW264.7 macrophages. Jin J(1), Lu Z(2), Li Y(1), Ru JH(1), Lopes-Virella MF(1)(2), Huang Y(1)(2).

Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.

13. Eur J Intern Med. 2017 Jan;37:25-32. doi: 10.1016/j.ejim.2016.07.011. Epub 2016 Aug 10. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Belmatoug N(1), Di Rocco M(2), Fraga C(3), Giraldo P(4), Hughes D(5), Lukina E(6), Mai

C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.

14. Tumour Biol. 2016 Aug;37(8):11039-48. doi: 10.1007/s13277-015-4598-1. Epub 2016 Feb 20. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor. Liu M(1), Gu P(1), Guo W(2), Fan X(3). Author information: (1)Department of Intervent

Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice.

15. Mol Genet Metab. 2012 Apr;105(4):621-8. doi: 10.1016/j.ymgme.2012.01.020. Epub 2012 Feb 1. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice. Nietupski JB(1), Pacheco JJ, Chuang WL, Marate

Clinical pharmacokinetics of fingolimod.

44. Clin Pharmacokinet. 2012 Jan 1;51(1):15-28. doi: 10.2165/11596550-000000000-00000. Clinical pharmacokinetics of fingolimod. David OJ(1), Kovarik JM, Schmouder RL. Author information: (1)Novartis Institutes for Biomedical Research, Basel, Switzerland. olivier.david@novartis.com Fingolimod (

Lipidomics in Periodontal Disease Research: A Systematic Review.

20. Curr Med Chem. 2025;32(19):3825-3849. doi: 10.2174/0109298673323591240923051742. Lipidomics in Periodontal Disease Research: A Systematic Review. Silva C(1)(2), Peixoto F(3), Dias I(1)(2), Domingues R(4)(5), Viegas C(1)(2)(6). Author information: (1)Department of Veterinary Sciences, School o